Janus Henderson Group PLC Sells 70,334 Shares of Sanofi $SNY

Janus Henderson Group PLC decreased its position in Sanofi (NASDAQ:SNY) by 9.9% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 642,277 shares of the company’s stock after selling 70,334 shares during the period. Janus Henderson Group PLC’s holdings in Sanofi were worth $30,941,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after buying an additional 1,869 shares in the last quarter. AQR Capital Management LLC raised its position in Sanofi by 107.2% during the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after acquiring an additional 15,791 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Sanofi by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after acquiring an additional 752 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in Sanofi by 5.4% in the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after acquiring an additional 347 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in shares of Sanofi by 36.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock valued at $159,000 after acquiring an additional 875 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $43.08 on Monday. The firm has a market cap of $104.44 billion, a P/E ratio of 22.55, a price-to-earnings-growth ratio of 1.15 and a beta of 0.35. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21. Sanofi has a 1-year low of $40.89 and a 1-year high of $52.68. The business’s 50 day moving average is $43.43 and its 200-day moving average is $45.19.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SNY. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Morgan Stanley set a $49.00 price objective on Sanofi in a research note on Wednesday, July 8th. Finally, Argus upgraded Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $49.50.

Trending Headlines about Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi reported second-quarter earnings of $1.19 per share, exceeding the $1.10 analyst consensus, while revenue rose 16% year over year to $14.04 billion, above expectations of $13.02 billion. Sanofi quarterly earnings report
• Positive Sentiment: Strong demand for blockbuster immunology drug Dupixent drove the results, with quarterly sales surpassing €5 billion for the first time. The performance led Sanofi to raise its 2026 outlook, targeting roughly 10% sales growth excluding currency effects and slightly faster growth in business earnings per share. Sanofi raises sales outlook on Dupixent strength
• Neutral Sentiment: Unusually high options activity showed traders purchased 4,046 call options, 74% above average daily volume. This may indicate increased bullish speculation, but it does not necessarily signal a change in the company’s fundamentals.
• Negative Sentiment: Management acknowledged that weak decision-making and execution hurt the pipeline. The new CEO plans to overhaul and prioritize R&D, raising concerns about the timing and strength of future product launches. Sanofi discusses pipeline and R&D discipline
• Negative Sentiment: The positive earnings and guidance news was overshadowed by pipeline setbacks, leaving investors focused on whether Dupixent’s momentum can offset longer-term portfolio risks. Sanofi beats earnings but faces pipeline setbacks

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.